Comments
Domestic pharma major Lupin Ltd today said it has launched in the US market its generic version of Moxifloxacin Hydrochloride Ophthalmic solution used for treating bacterial conjunctivitis.
The launch follows receipt of approval from the US Food and Drug Administration (USFDA) earlier for Moxifloxacin Hydrochloride Ophthalmic solution 0.5 per cent, the company said in a statement.
The product is produced at Lupin’s Pithampur manufacturing facility, it added.
The medicine is the generic equivalent of Novartis Pharma Corp’s Vigamox Ophthalmic solution.
Shares of Lupin were trading at Rs 1,063 apiece in mid-day trade, up 1.80 per cent from the previous close on BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.